USOR 22198 - STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles